Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors

por Zang, Yan, Kirk, Christopher J, Johnson, Daniel E
Publicado em 2014

Complex changes in cellular inositol phosphate complement accompany transit through the cell cycle.

por Barker, Christopher J, Wright, Joanne, Hughes, Philip J, Kirk, Christopher J, Michell, Robert H
Publicado em 2004

Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis

por Basler, Michael, Mundt, Sarah, Muchamuel, Tony, Moll, Carlo, Jiang, Jing, Groettrup, Marcus, Kirk, Christopher J
Publicado em 2014

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells

por Suzuki, Erika, Demo, Susan, Deu, Edgar, Keats, Jonathan, Arastu-Kapur, Shirin, Bergsagel, P. Leif, Bennett, Mark K., Kirk, Christopher J.
Publicado em 2011

PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7, Blocks Multiple Myeloma Cell Growth both in Vitro and in Vivo

por Singh, Ajita V., Bandi, Madhavi, Aujay, Monette A, Kirk, Christopher J, Hark, David E., Raje, Noopur, Chauhan, Dharminder, Anderson, Kenneth C.
Publicado em 2010

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

por Chauhan, Dharminder, Singh, Ajita V., Aujay, Monette, Kirk, Christopher J., Bandi, Madhavi, Ciccarelli, Bryan, Raje, Noopur, Richardson, Paul, Anderson, Kenneth C.
Publicado em 2010

Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities are Enhanced by Suppression of Mcl-1 or Autophagy

por Zang, Yan, Thomas, Sufi M., Chan, Elena T., Kirk, Christopher J., Freilino, Maria L., DeLancey, Hannah M., Grandis, Jennifer R., Li, Changyou, Johnson, Daniel E.
Publicado em 2012

The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4

por Zang, Yan, Thomas, Sufi M., Chan, Elena T., Kirk, Christopher J., Freilino, Maria L., DeLancey, Hannah M., Grandis, Jennifer R., Li, Changyou, Johnson, Daniel E.
Publicado em 2012

Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity

por Li, Hao, Ponder, Elizabeth L., Verdoes, Martijn, Asbjornsdottir, Kristijana H., Deu, Edgar, Edgington, Laura E., Lee, Jeong Tae, Kirk, Christopher J., Demo, Susan D., Williamson, Kim C., Bogyo, Matthew
Publicado em 2012

Novel Proteasome Inhibitors Have a Beneficial Effect in Murine Lupus via the dual inhibition of Type I Interferon and autoantibody secreting cells

por Ichikawa, H. Travis, Conley, Thomas, Muchamuel, Tony, Jiang, Jing, Lee, Susan, Owen, Teresa, Barnard, Jennifer, Nevarez, Sarah, Goldman, Bruce I., Kirk, Christopher J., Looney, R. John, Anolik, Jennifer H.
Publicado no Arthritis Rheum (2012)

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines

por Niewerth, Denise, Kaspers, Gertjan JL, Assaraf, Yehuda G, van Meerloo, Johan, Kirk, Christopher J, Anderl, Janet, Blank, Jonathan L, van de Ven, Peter M, Zweegman, Sonja, Jansen, Gerrit, Cloos, Jacqueline
Publicado em 2014

Co‐inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity

por Basler, Michael, Lindstrom, Michelle M, LaStant, Jacob J, Bradshaw, J Michael, Owens, Timothy D, Schmidt, Christian, Maurits, Elmer, Tsu, Christopher, Overkleeft, Herman S, Kirk, Christopher J, Langrish, Claire L, Groettrup, Marcus
Publicado no EMBO Rep (2018)

Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors

por Niewerth, Denise, Franke, Niels E., Jansen, Gerrit, Assaraf, Yehuda G., van Meerloo, Johan, Kirk, Christopher J., Degenhardt, Jeremiah, Anderl, Janet, Schimmer, Aaron D., Zweegman, Sonja, de Haas, Valerie, Horton, Terzah M., Kaspers, Gertjan J.L., Cloos, Jacqueline
Publicado em 2013

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay

por Lee, Susan J., Levitsky, Konstantin, Parlati, Francesco, Bennett, Mark K., Arastu‐Kapur, Shirin, Kellerman, Lois, Woo, Tina F., Wong, Alvin F., Papadopoulos, Kyriakos P., Niesvizky, Ruben, Badros, Ashraf Z., Vij, Ravi, Jagannath, Sundar, Siegel, David, Wang, Michael, Ahmann, Gregory J., Kirk, Christopher J.
Publicado no Br J Haematol (2016)

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

por Verbrugge Sue Ellen, Al Marjon, Assaraf Yehuda G, Niewerth Denise, van Meerloo Johan, Cloos Jacqueline, van der Veer Michael, Scheffer George L, Peters Godefridus J, Chan Elena T, Anderl Janet L, Kirk Christopher J, Zweegman Sonja, Dijkmans Ben AC, Lems Willem F, Scheper Rik J, de Gruijl Tanja D, Jansen Gerrit
Publicado em 2013-01-01

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

por Verbrugge, Sue Ellen, Al, Marjon, Assaraf, Yehuda G, Niewerth, Denise, van Meerloo, Johan, Cloos, Jacqueline, van der Veer, Michael, Scheffer, George L, Peters, Godefridus J, Chan, Elena T, Anderl, Janet L, Kirk, Christopher J, Zweegman, Sonja, Dijkmans, Ben AC, Lems, Willem F, Scheper, Rik J, de Gruijl, Tanja D, Jansen, Gerrit
Publicado em 2013